Nirsevimab has been shown to be highly effective in preventing respiratory syncytial virus (RSV) infection in healthy infants, but its effectiveness in high-risk populations such as preterm infants or those with congenital heart disease (CHD) remains uncertain due to limited real-world evidence. To address this gap, a study evaluated whether nirsevimab administration is associated with reduced RSV-related hospitalizations among 179 at-risk infants.
The study found that among 177 matched RSV-related lower respiratory tract infection (LRTI) hospitalization cases and 708 control infants, nirsevimab uptake was lower in cases (156/177, 88.1%) compared with controls (689/708, 97.3%). Nirsevimab was associated with a reduced risk of RSV-related hospitalization of 84.3% among all at-risk infants, 85.1% among high-risk infants (extreme prematurity and CHD), and 96.3% among infants with CHD, but…
